Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

Publikation

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

Wissenschaftlicher Artikel/Review - 02.04.2022

Rischin Danny, Harrington Kevin J, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Brana Irene, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Ishak Wan Zamaniah Wan, Hong Ruey-Long, Mendoza René Gonzalez, Jia Liyi, Chirovsky Diana, Norquist Josephine, Jin Fan, Burtness Barbara

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

Norquist, Josephine

Jin, Fan

Burtness, Barbara